Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent

(2019) James G. Krings et al.   Journal of Allergy and Clinical Immunology-In Practice

Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response

(2019) Marco Caminati et al.   Expert Review of Respiratory Medicine

Mepolizumab in the treatment of severe eosinophilic asthma

(2018) Ronald A. Strauss et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

After asthma: redefining airways diseases

(2018) Ian D Pavord et al.   LANCET

Severe eosinophilic asthma: a roadmap to consensus

(2017) Roland Buhl et al.   EUROPEAN RESPIRATORY JOURNAL

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

(2017) Akbar K Waljee et al.   BMJ-British Medical Journal

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

(2017) Akbar K Waljee et al.   BMJ-British Medical Journal

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting

(2016) Robert S. Zeiger et al.   Journal of Allergy and Clinical Immunology-In Practice

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

(2011) H. Quan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review

(2011) Evelyn Sarnes et al.   CLINICAL THERAPEUTICS

Risk factors for death in adults with severe asthma

(2010) Theodore A. Omachi et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY